Ampio Pharmaceuticals (AMPE) Stock Price, News & Analysis

Company Overview

Ampio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and degenerative diseases. The company’s primary area of interest has been osteoarthritis of the knee, a condition characterized by cartilage breakdown, pain and inflammation.

Ampio’s lead investigational product has been Ampion, an intra-articular injection designed to provide anti-inflammatory effects in the knee. The product has been evaluated in clinical studies involving patients with osteoarthritis, including individuals with severe disease. Ampion is an investigational therapy and has not been established as an approved commercial treatment.

Based in Englewood, Colorado, Ampio has conducted its research and clinical-development activities primarily in the United States. The company has historically focused its resources on advancing Ampion through regulatory and clinical evaluation rather than marketing an established portfolio of pharmaceutical products. Information about its current leadership and development pipeline may change as the company’s clinical strategy evolves.

Key Stats

• Today's Range: $0.18 to $0.18
• 50-Day Range: $0.18 to $0.18
• 52-Week Range: $0.00 to $0.64
• Volume: N/A
• Average Volume: 2,326 shs
• Market Capitalization: $207.82 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 11/10/2021
• Today: 9/24/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:AMPE
• CIK: 1411906
• Web: ampiopharma.com
• Phone: 720-437-6500
• Fax: 720-437-6501
• Employees: 6
• Year Founded: 2010

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.04 per share
• Price / Book: 0.05

Miscellaneous

• Outstanding Shares: 1,135,000
• Free Float: 1,098,000
• Market Cap: $207.82 thousand
• Optionable: No Data
• Beta: 5.96